Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Sanguine's PHER-02 development

June 7, 1996

Amgen initiates first leptin clinical study

June 7, 1996

NO-1886 in phase II clinical trials

June 7, 1996

Sankyo discovers ACAT inhibitor

June 7, 1996

Hoescht reports imidobisphosphonic acid derivatives

June 7, 1996

Fujisawa claims ACAT inhibitors

June 7, 1996

Completion of phase I clinical trials on human red blood cell substitute

May 31, 1996

Celtrix announces the initiation of two phase I trials of SomatoKine

May 31, 1996

ACAT inhibitors from Warner-Lambert

May 31, 1996

Multicenter clinical trial indicates alendronate effective in osteoporotic fracture prevention

May 31, 1996

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...